Physician profile
David Wilkinson
NPI 1407905847
$215,569.69
in general payments reported to CMS, 2019-2025
48 companies · $3,114 in 2025
The $3,114 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $72K · 2021: $77K · 2022: $12K · 2023: $3,147 · 2024: $5,790 · 2025: $3,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,734 · Travel and Lodging: $2,231 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,734.06 |
| Travel and Lodging | $2,231.35 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $105,382.70 | 2019-2020 | |
| Teleflex LLC | $101,283.32 | 2020-2025 | Urolift, Barrigel |
| Axonics, INC. | $2,878.21 | 2020-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $982.71 | 2019-2021 | |
| Boston Scientific Corporation | $701.35 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml, Spaceoar System |
| Coloplast Corp | $553.41 | 2019-2024 | |
| Pfizer INC. | $294.41 | 2019-2021 | |
| Janssen Biotech, INC. | $286.14 | 2019-2025 | Erleada |
| Calyxo, INC. | $283.15 | 2022-2025 | Cvac Aspiration System |
| Abbvie INC. | $256.05 | 2019-2025 | Botox |
| Ferring Pharmaceuticals INC. | $246.89 | 2019-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $202.43 | 2020-2025 | |
| Endo Pharmaceuticals INC. | $173.58 | 2019-2021 | |
| Urogen Pharma, INC. | $138.63 | 2021-2025 | |
| Blue Earth Diagnostics | $129.24 | 2019-2025 | Posluma |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.